In conclusion, FAKTION met its primary outcome in showing that the combination of fulvestrant and capivasertib is tolerable and produces a significant improvement in progression-free survival for participants with advanced oestrogen receptor-positive HER2-negative breast cancer who have previously progressed on an aromatase inhibitor. The gene discussed is ERBB2; the disease is breast carcinoma.